{
  "paper_id": "PMC7833659",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833659/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "Odds of COVID-19 infection in patients with recent versus all-time diagnosis of hematologic malignancies, adjusted for age, gender, race and potential COVID-19 risk factors (cardiovascular diseases, type 2 diabetes, obesity, chronic kidney diseases, chronic obstructive pulmonary disease (COPD), asthma, substance use disorders, cancer therapy (chemotherapy, radiotherapy, immunotherapy), transplant procedure (bone marrow transplant, solid organ transplant) and nursing home stay status.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/1a1bcc820c60/gr1_lrg.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/1a1bcc820c60/gr1_lrg.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/1a1bcc820c60/gr1_lrg.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/1a1bcc820c60/gr1_lrg.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f0005",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/1a1bcc820c60/gr1_lrg.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7833659/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/1a1bcc820c60/gr1_lrg.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2.",
      "caption": "Effects of demographics on odds of COVID-19 infection among patients with recently diagnosed hematologic malignancies, adjusted for other demographics and potential COVID-19 risk factors (cardiovascular diseases, type 2 diabetes, obesity, chronic kidney diseases, chronic obstructive pulmonary disease (COPD), asthma, substance use disorders, cancer therapy (chemotherapy, radiotherapy, immunotherapy), transplant procedure (bone marrow transplant, solid organ transplant) and nursing home stay status.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/afacbc8c949f/gr2_lrg.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/afacbc8c949f/gr2_lrg.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/afacbc8c949f/gr2_lrg.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/afacbc8c949f/gr2_lrg.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f0010",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/afacbc8c949f/gr2_lrg.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7833659/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/afacbc8c949f/gr2_lrg.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3.",
      "caption": "Hospitalization and death rates among three populations: patients with both recent diagnosis of hematologic malignancies and COVID-19, COVID-19 patients without hematologic malignancies, hematologic malignancy patients without COVID-19. ***: p < 0.0001; **: p < 0.001; ns: not statistically significant. The SNOMED-CT concepts “Hospital admission (procedure)” (ID 32485007) was used to obtain hospitalization status from patient EHRs. Explorys regularly imports from the Social Security Death index for the “deceased” status.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/f7cb917d6112/gr3_lrg.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/f7cb917d6112/gr3_lrg.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/f7cb917d6112/gr3_lrg.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/f7cb917d6112/gr3_lrg.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f0015",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/f7cb917d6112/gr3_lrg.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7833659/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f90/7833659/f7cb917d6112/gr3_lrg.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Of the eight hematologic malignancies types, patients with recent diagnosis of acute lymphoid leukemia had the largest odds of COVID-19 infection, followed by essential thrombocythemia, acute myeloid leukemia, multiple myeloma, chronic lymphoid leukemia, Non-Hodgkin lymphoma, myelodysplastic syndrome and polycythemia vera (Fig. 1\ntop).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Compared with patients with recent diagnosis of hematologic malignancies, patients with all-time diagnosis had lower odds of COVID-19 infection (AOR: 2.27 [2.17–2.36], p < 0.001), with the strongest effect for acute lymphoid leukemia followed by essential thrombocythemia, multiple myeloma, acute myeloid leukemia, Non-Hodgkin lymphoma, chronic lymphoid leukemia, polycythemia vera and myelodysplastic syndrome (Fig. 1 bottom).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Of the eight hematologic malignancies types, patients with recent diagnosis of acute lymphoid leukemia had the largest odds of COVID-19 infection, followed by essential thrombocythemia, acute myeloid leukemia, multiple myeloma, chronic lymphoid leukemia, Non-Hodgkin lymphoma, myelodysplastic syndrome and polycythemia vera (Fig. 1\ntop).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Compared with patients with recent diagnosis of hematologic malignancies, patients with all-time diagnosis had lower odds of COVID-19 infection (AOR: 2.27 [2.17–2.36], p < 0.001), with the strongest effect for acute lymphoid leukemia followed by essential thrombocythemia, multiple myeloma, acute myeloid leukemia, Non-Hodgkin lymphoma, chronic lymphoid leukemia, polycythemia vera and myelodysplastic syndrome (Fig. 1 bottom).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 4,
    "images_downloaded": 3,
    "tables_filtered": 29
  }
}